Research Projects & Grants

For Profit Organization

  • A U.S. post-approval study of the PROMUS Element™ plus everolimus-eluting platinum chromium coronary stent system, Role: PI, Boston Scientific Corp., (03/2018 - 03/2019) Status: Completed
  • ARTEMIS D5130R00030: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study, Role: PI, AstraZeneca (UK HQ), (07/2017 - 07/2018) Status: Completed
  • AXERA Access safety and efficacy post endovascular intervention (ASPEN), Role: PI, Arstasis, Inc., (02/2015 - 02/2016) Status: Completed
  • Humanitarian Use Device: Medtronic melody transcatheter pulmonary valve and Medtronic ensemble transcatheter valve delivery system, Role: Investigator, Medtronic, Inc., (09/2014 - 09/2015) Status: Completed
  • OMEGA: A prospective, multicenter single-arm trial to assess the OMEGA coronary stent system for the treatment of a single de novo coronary artery lesion, Role: PI, Boston Scientific Corp., (06/2013 - 06/2014) Status: Completed
  • The TRANSLATE-ACS study: Treatment with ADP receptor inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome, Role: PI, Eli Lilly & Co., (05/2013 - 05/2014) Status: Completed

Internal

  • HUD: PK Papyrus Covered Coronary Stent System, Role: PI, LLU Dept. of Medicine, (04/2025 - 04/2026) Status: Approved
  • Evaluation of clinical impact of non-invasive hemodynamic monitoring to optimize preventive care of heart failure patients, Role: Investigator, LLU Dept. of Anesthesiology, (09/2020 - 09/2021) Status: Completed
  • National cardiogenic shock initiative, Role: Investigator, LLU Dept. of Cardiology, (07/2020 - 07/2021) Status: Completed
  • A Retrospective Analysis and Review of Patients Undergoing Impella, a Temporary Left Ventricular Support Device, Implantation for Complex Coronary Intervention or Cardiogenic Shock, Role: Investigator, LLU Dept. of Medicine, (04/2020) Status: Approved
  • Cardiovascular Disease in SARS-Coronavirus 2 (SARS-CoV-2), Role: Investigator, LLU Dept. of Medicine, (04/2020) Status: Approved
  • Morbidity and mortality associated with the current practice of inotrope administration in CCU, Role: Investigator, LLU Dept. of Medicine, (02/2019) Status: Approved

Non-Profit Organization

  • Cardiovascular inflammation reduction trial (CIRT): a randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose Methotrexate(LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome, Role: Investigator, Brigham & Women's Hospital, (08/2017 - 08/2018) Status: Completed